• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

卡介苗治疗失败后非肌层浸润性膀胱癌患者对膀胱内吉西他滨的完全缓解：一例报告及文献综述

Complete response to intravesical gemcitabine in non-muscle invasive bladder cancer patient after BCG failure: A case report and literature review.

作者信息

Nahhat Fouad, Doyya Modar, Ksiri Hazem

机构信息

Faculty of Medicine Damascus University Damascus Syria.

Department of Oncology Albairouni University Hospital Damascus Syria.

出版信息

Clin Case Rep. 2022 Sep 22;10(9):e6373. doi: 10.1002/ccr3.6373. eCollection 2022 Sep.

DOI:10.1002/ccr3.6373
PMID:36188034
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9500417/
Abstract

Bladder cancer treatment remains a challenge to every oncologist. We report the case of a 57-year-old man with BCG-refractory bladder cancer who had a complete response to intravesical gemcitabine to highlight the role of gemcitabine as a bladder sparing treatment in BCG-failure patients.

摘要

膀胱癌的治疗对每位肿瘤学家来说仍然是一项挑战。我们报告了一例57岁卡介苗难治性膀胱癌男性患者，其对膀胱内注射吉西他滨有完全反应，以突出吉西他滨在卡介苗治疗失败患者中作为保留膀胱治疗的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46b2/9500417/6f75dcdcadfd/CCR3-10-e6373-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46b2/9500417/6f75dcdcadfd/CCR3-10-e6373-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46b2/9500417/6f75dcdcadfd/CCR3-10-e6373-g001.jpg

相似文献

1
Complete response to intravesical gemcitabine in non-muscle invasive bladder cancer patient after BCG failure: A case report and literature review.卡介苗治疗失败后非肌层浸润性膀胱癌患者对膀胱内吉西他滨的完全缓解：一例报告及文献综述
Clin Case Rep. 2022 Sep 22;10(9):e6373. doi: 10.1002/ccr3.6373. eCollection 2022 Sep.
2
Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.经尿道膀胱内吉西他滨治疗非肌层浸润性膀胱癌（NMIBC）：系统评价。
BJU Int. 2012 Feb;109(4):496-505. doi: 10.1111/j.1464-410X.2011.10880.x.
3
Intravesical gemcitabine for non-muscle invasive bladder cancer.膀胱内注射吉西他滨治疗非肌层浸润性膀胱癌。
Cochrane Database Syst Rev. 2012 Jan 18;1:CD009294. doi: 10.1002/14651858.CD009294.pub2.
4
Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non-muscle-invasive bladder cancer after BCG failure.中期随访（3 年）证实并扩展了吉西他滨膀胱内治疗在卡介苗治疗失败后作为非肌肉浸润性膀胱癌保膀胱治疗的短期结果。
Urol Oncol. 2021 Mar;39(3):195.e7-195.e13. doi: 10.1016/j.urolonc.2020.09.017. Epub 2020 Oct 23.
5
Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure.卡介苗治疗失败后的高危非肌肉浸润性膀胱癌行膀胱内吉西他滨灌注治疗。
J Urol. 2013 Nov;190(5):1686-91. doi: 10.1016/j.juro.2013.04.120. Epub 2013 May 7.
6
Intravesical gemcitabine for non-muscle invasive bladder cancer.膀胱内吉西他滨治疗非肌肉浸润性膀胱癌。
Cochrane Database Syst Rev. 2021 Jun 14;6(6):CD009294. doi: 10.1002/14651858.CD009294.pub3.
7
Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy.顺次膀胱内给予吉西他滨/多西他赛在卡介苗治疗后复发的高危非肌层浸润性膀胱癌患者中提供持久缓解。
Urol Oncol. 2023 Nov;41(11):458.e1-458.e7. doi: 10.1016/j.urolonc.2023.06.018. Epub 2023 Sep 9.
8
Intravesical Gemcitabine versus Intravesical Bacillus Calmette-Guérin for the Treatment of Non-Muscle Invasive Bladder Cancer: An Evaluation of Efficacy and Toxicity.膀胱内注射吉西他滨与膀胱内注射卡介苗治疗非肌层浸润性膀胱癌：疗效与毒性评估
Front Oncol. 2017 Nov 2;7:260. doi: 10.3389/fonc.2017.00260. eCollection 2017.
9
Intravesical Gemcitabine versus Intravesical Bacillus Calmette-Guerin for the Treatment of Intermediate-Risk Non-Muscle Invasive Bladder Cancer: A Randomized Controlled Trial.膀胱内注射吉西他滨与膀胱内注射卡介苗治疗中危非肌层浸润性膀胱癌的随机对照试验
Urol J. 2023 Feb 27;20(2):123-128. doi: 10.22037/uj.v19i.7194.
10
The efficacy and safety outcomes of lower dose BCG compared to intravesical chemotherapy in non-muscle-invasive bladder cancer: A network meta-analysis.低剂量卡介苗与膀胱内化疗治疗非肌肉浸润性膀胱癌的疗效和安全性结局：一项网络荟萃分析。
Urol Oncol. 2023 Jun;41(6):261-273. doi: 10.1016/j.urolonc.2023.04.003. Epub 2023 May 2.

本文引用的文献

1
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).欧洲泌尿外科学会非肌层浸润性膀胱癌（Ta、T1和原位癌）指南
Eur Urol. 2022 Jan;81(1):75-94. doi: 10.1016/j.eururo.2021.08.010. Epub 2021 Sep 10.
2
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
3
Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial.
膀胱内吉西他滨与丝裂霉素用于非肌肉浸润性膀胱癌：随机对照试验的系统评价和荟萃分析。
BMC Urol. 2020 Jul 13;20(1):97. doi: 10.1186/s12894-020-00610-9.
4
Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: how, when and what.非肌层浸润性膀胱癌膀胱内治疗的最新进展：如何、何时以及何种治疗。
World J Urol. 2019 Oct;37(10):2017-2029. doi: 10.1007/s00345-018-2591-1. Epub 2018 Dec 7.
5
The efficacy and safety of intravesical gemcitabine vs Bacille Calmette-Guérin for adjuvant treatment of non-muscle invasive bladder cancer: a meta-analysis.膀胱内注射吉西他滨与卡介苗用于非肌层浸润性膀胱癌辅助治疗的疗效和安全性：一项荟萃分析。
Onco Targets Ther. 2018 Aug 8;11:4641-4649. doi: 10.2147/OTT.S170477. eCollection 2018.
6
[Systematic review on conservative treatment options in non-muscle-invasive bladder cancer patients refractory to Bacillus Calmette-Guérin instillation therapy].[卡介苗膀胱灌注治疗难治性非肌层浸润性膀胱癌患者保守治疗方案的系统评价]
Aktuelle Urol. 2017 Aug;48(4):314-328. doi: 10.1055/s-0043-108944. Epub 2017 Jun 13.
7
Failure of Bacillus Calmette-Guérin therapy in non-muscle-invasive bladder cancer: Definition and treatment options.卡介苗治疗非肌层浸润性膀胱癌失败：定义及治疗选择
Arch Esp Urol. 2016 Sep;69(7):423-33.
8
A systematic review and meta-analysis of quality of life outcomes after radical cystectomy for bladder cancer.膀胱癌根治性膀胱切除术后生活质量结局的系统评价与荟萃分析。
Surg Oncol. 2016 Sep;25(3):281-97. doi: 10.1016/j.suronc.2016.05.027. Epub 2016 Jun 7.
9
High-Risk Non-Muscle-Invasive Bladder Cancer-Therapy Options During Intravesical BCG Shortage.高危非肌层浸润性膀胱癌——卡介苗膀胱灌注短缺期间的治疗选择
Curr Urol Rep. 2016 Sep;17(9):68. doi: 10.1007/s11934-016-0625-z.
10
Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group.非肌层浸润性膀胱癌的定义、终点指标及临床试验设计：国际膀胱癌小组的建议
J Clin Oncol. 2016 Jun 1;34(16):1935-44. doi: 10.1200/JCO.2015.64.4070. Epub 2016 Jan 25.